• Dovato Noninferior to Biktarvy at 48 Weeks

    Dovato Noninferior to Biktarvy at 48 Weeks
    Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyA two-drug regimen of dolutegravir-lamivudine (DTG/3TC; Dovato, ViiV Healthcare) was noninferior to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) for virologic suppression at 48 weeks among adults initiating antiretroviral therapy, according to results from the phase 3b VOGUE trial presented at AIDS 2026, in Rio de Janeiro (oral presentation OAB0106LB and in-pers
  • GLP-1 Market Drives Specialty Pipeline Expansion

    GLP-1 Market Drives Specialty Pipeline Expansion
    Originally published by our sister publication Specialty Pharmacy ContinuumBy Karen BlumGlucagon-like peptide-1 (GLP-1) medications for the management of obesity and type 2 diabetes will continue to dominate the specialty pipeline in 2026, including oral options, novel targets, and dual agents.GLP-1 product sales hit approximately $132 billion in 2025, said Dan Powell, PharmD, the patient solutions manager and pharmacist-in-charge of the Walgreens Gene and Cell Services Pharmacy, in Pittsburgh,

Follow @newsl_pharmacy on Twitter!